SciSparc-Clearmind Medicine File International Patent for New MDMA Treatment

TEL AVIV, Israel, Sept. 06, 2024 – SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company dedicated to developing therapies for central nervous system disorders and rare diseases, announced a significant milestone in its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND) (FSE: CWY0). Clearmind Medicine, a biotechnology company specializing in novel psychedelic-derived therapeutics for major mental health issues, has seen an international patent application published under the Patent Cooperation Treaty. This patent pertains to the innovative combination of 3,4-Methylenedioxymethamphetamine (MDMA) with N-Acylethanolamines.

The collaboration between SciSparc and Clearmind Medicine is focused on developing new therapeutic combinations that integrate psychedelic molecules with the N-Acylethanolamines family, including Palmitoylethanolamide (PEA). Clearmind has already filed thirteen related patents with the U.S. Patent and Trademark Office and in various global jurisdictions.

Oz Adler, Chief Executive Officer of SciSparc, emphasized the importance of this partnership in advancing safe and effective treatments. Adler stated, "Our collaboration with Clearmind underscores our commitment to providing effective and safe treatments. This announcement is a testament to our innovative approach, which integrates MDMA with N-Acylethanolamines like PEA. We aim to enhance the safety and therapeutic potential of these treatments. This combination offers a promising path forward for treating mental health disorders and addictions, potentially overcoming regulatory barriers and unlocking MDMA's full potential in clinical settings."

SciSparc Ltd. is led by a team of experienced executives and scientists focused on developing a portfolio of cannabinoid-based pharmaceutical technologies. The company is currently engaged in several drug development programs, including SCI-110 for treating Tourette Syndrome and Alzheimer's disease agitation, and SCI-210 for autism and status epilepticus. Additionally, SciSparc owns a controlling interest in a subsidiary that markets hemp seed oil-based products on Amazon.

Clearmind Medicine Inc. is a clinical-stage biotech company dedicated to discovering and developing novel psychedelic-derived therapeutics for widespread and underserved health issues, such as alcohol use disorder. The company’s primary goal is to research and commercialize these psychedelic-based compounds as regulated medicines, foods, or supplements. Clearmind's intellectual property portfolio includes nineteen patent families with 29 granted patents, and the company plans to seek additional patents and acquire more intellectual property to expand its portfolio.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!